Inhibition of the β1 integrin activity by monoclonal antibody AIIB2 could promote radiotherapy efficacy and elevates sensitivity to HER2‐targeting agents of breast cancer cells265, 266. The gene discussed is ERBB2; the disease is breast cancer.